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eﬁnition and diagnosis
hese  recommendations  are  not  limited  to  asymmetric  sep-
al  HCM  (formerly  called  ‘idiopathic’),  and  the  authors
ave  deliberately  chosen  to  place  them  in  a  practical  con-
ext.  The  discovery  of  HCM  must  be  based  on  clinical  and
chocardiographic  ﬁndings,  and  in  the  absence  of  load  con-
itions  that  could  explain  this  hypertrophy.  The  ESC  Task
orce  has  extended  the  deﬁnition  to  all  potential  HCM,
ut  expanding  the  aetiologies  and  thus  the  diagnostic  spec-
rum  has  made  readability  more  difﬁcult.  However,  these
ecommendations  appear  more  suited  to  routine  clinical
ractice.
The  main  aetiologies  are:  sarcomeric  HCM  (by  muta-
ions  in  cardiac  sarcomere  protein  genes),  which  represents
0—60%  of  conventional  forms  of  HCM;  unknown  causes
25—30%);  and  genetic  or  non-genetic  causes  (5—10%)
i.e.  metabolic  disorders,  mitochondrial  cardiomyopathies,
euromuscular  disease,  malformation  syndromes,  inﬁl-
rative  disease,  endocrine  disorders,  heart  disease  and
hronic  use  of  drugs  [anabolic  steroids,  hydroxychloroquine,
tc.]).
In adults,  HCM  is  deﬁned  by  a  wall  thickness  ≥  15  mm
>13  mm  in  ﬁrst-degree  relatives)  in  one  or  more  left  ven-
ricular  (LV)  myocardial  segments,  whatever  the  imaging
echnique  (echocardiography,  cardiac  magnetic  resonance
CMR]  or  computed  tomography),  without  any  explained
oading  conditions.  In  children,  the  diagnosis  of  HCM
equires  an  LV  wall  thickness  more  than  two  standard
eviations  greater  than  the  predicted  mean.  Diagnosis
f  HCM  is  based  on  a  careful  analysis  of  the  baseline
ssessment  (age,  family  history,  clinical  examination,  elec-
rocardiogram  [ECG]  and  echocardiography),  leading  to
he  realisation  of  other  examinations  (imaging,  biology,
enetic  testing)  and  the  eventual  suggestion  of  speciﬁc
etiologies.  In  neonates  and  children,  inherited  metabolic
isorders  and  congenital  dysmorphic  syndromes  should  be
onsidered,  whereas  in  subjects  aged  >  65  years,  amylose
ecomes  a  more  likely  cause.  The  clinical  examination  may
uggest  some  aetiologies  (e.g.  gait  disturbance  for  Friedre-
ch’s  ataxia,  learning  difﬁculties  and  mental  retardation
or  mitochondrial  diseases,  Noonan  syndrome  or  Danon  dis-
ase  and  angiokeratomata  for  Fabry  disease).  Concerning
CG  abnormalities,  a  short  PR  interval  suggests  stor-
ge  diseases  (Pompe  disease,  PRKAG2  and  Danon  disease)
nd  mitochondrial  disorders.  Several  biomarkers  should  be
easured  in  routine  practice  (creatine  kinase;  renal  and
iver  function  tests;  haematology  tests).  Alpha  galactosi-
ase  A  may  be  of  interest  in  men  aged  >  30  years  (Fabry
isease).
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ssessment of symptoms, severity and risk
f  progression
chocardiography  is  the  gold  standard  for  the  diagnosis  and
ssessment  of  HCM;  it  comprises  the  measurement  of  LV  wall
hickness  at  end-diastole,  preferentially  in  short-axis  views.
he  presence  or  absence  of  a  left  ventricular  outﬂow  tract
LVOT)  obstruction  must  be  assessed  at  rest  and  during  phys-
ological  provocation,  such  as  the  Valsalva  manoeuvre.  The
hreshold  remains  at  30  mmHg  for  the  instantaneous  peak
oppler  LV  outﬂow  tract  pressure  gradient  at  rest,  and  exer-
ise  echocardiography  is  not  recommended  in  asymptomatic
atients  with  a  gradient  >  50  mmHg  at  rest.  The  use  of  con-
rast  echocardiography  is  of  interest  when  the  apex  is  poorly
isualized  by  ultrasound  (and/or  in  substitution  of  CMR),  and
t  may  also  be  performed  in  septal  alcohol  ablation.  Tran-
oesophageal  echocardiography  is  only  reserved  for  patients
ho  are  going  to  have  a  myomectomy  or  in  patients  with
oor  transthoracic  echocardiography  windows.
CMR  is  the  reference  imaging  examination,  but  must  be
erformed  and  interpreted  by  trained  teams  experienced  in
ardiac  imaging  and  in  the  evaluation  of  heart  muscle  dis-
ase.  Delayed  enhancement  can  assess  ﬁbrosis,  but  CMR  is
specially  recommended  in  terms  of  accurate  visualization
f  anatomical  abnormalities  and/or  evaluation  of  morphol-
gy  and  ventricular  function.  However,  the  prognostic  value
f  CMR  is  not  clear;  late  enhancement  is  common  in  HCM
nd  there  is  insufﬁcient  evidence  to  give  it  real  decision-
aking  power  regarding  the  implantation  of  an  implantable
ardioverter  deﬁbrillator  (ICD).
Exercise  testing  is  useful  for  the  assessment  of  functional
apacity,  potential  occurrence  of  arrhythmia  and  blood  pres-
ure  proﬁle,  but  also  the  appearance  of  the  gradient  and  its
xercise  tolerance.  Cardiopulmonary  exercise  testing  with
imultaneous  measurement  of  respiratory  gases  is  recom-
ended  for  very  symptomatic  patients  or  for  the  assessment
f  exercise  intolerance.  Patients  with  typical  angina  on
xertion  should  be  considered  for  invasive  or  computed
omography  coronary  angiography.
The  occurrence  of  syncope  should  lead  to  a  consultation,
ith  an  ECG,  an  upright  exercise  test  and  48-hour  ambula-
ory  ECG  monitoring;  in  patients  with  recurrent  episodes  of
nexplained  syncope,  an  implantable  loop  recorder  should
e  considered.  The  occurrence  of  palpitations  should  lead
o  a  48-hour  Holter  ECG.  Electrophysiological  testing  is  not
ecommended  for  risk  stratiﬁcation  or  for  the  exploration  of
yncope;  testing  is  indicated  for  the  assessment  of  persistent
r  recurrent  supraventricular  tachycardia,  for  ventricular
re-excitation  or  for  sustained  monomorphic  ventricular
achycardia.
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Genetic counselling and family screening
Genetic  counselling  is  recommended  for  all  patients  with
HCM  (whatever  the  familial  context),  unless  an  acquired
cause  has  been  demonstrated.  The  counselling  should  be
performed  by  a  professional  trained  for  this  speciﬁc  task,
and  should  deal  with  information  about  the  genetic  origin  of
HCM  and  the  various  implications  it  may  have  for  the  patient
and  the  whole  family,  including  modalities  for  optimal  medi-
cal  screening  and  follow-up  in  the  family.
Genetic  testing  is  recommended  in  the  proband  (the  ﬁrst
patient  diagnosed  for  HCM  within  the  family)  to  enable
cascade  genetic  screening  of  the  relatives.  Genetic  test-
ing  should  be  performed  in  certiﬁed  diagnostic  laboratories
with  expertise  in  that  ﬁeld.  Post-mortem  analyses  might
be  considered  if  the  proband  is  deceased  and  tissue  has
been  stored.  When  a  causative  mutation  is  identiﬁed  in  the
proband,  then  predictive  genetic  testing  is  recommended  in
ﬁrst-degree  relatives,  after  careful  pre-test  counselling,  to
guide  the  cardiac  management  of  these  relatives.
Relatives  who  do  not  carry  the  mutation  can  be  dis-
charged  from  further  follow-up,  whereas  relatives  who  carry
the  mutation  will  beneﬁt  from  a  cardiac  evaluation  and
follow-up.  If  no  causative  mutation  was  characterised  in  the
proband  with  HCM,  then  family  screening  is  solely  based  on
cardiac  screening  with  ECG  and  echocardiography,  which
should  be  considered  in  ﬁrst-degree  relatives  aged  ≥  10
years,  and  should  be  repeated  every  1  or  2  years  between
10—20  years  of  age  and  every  2  or  5  years  thereafter,  as
delayed  cardiac  expression  of  HCM  is  observed  quite  often,
even  in  adults.
For  the  situation  of  a  mutation  carrier  without  car-
diac  expression  (preclinical  phase  of  HCM),  the  guidelines
mention  that  sporting  activity  may  be  allowed,  taken  into
account  the  type  of  sport,  the  underlying  mutated  gene  and
the  results  of  regular  and  repeated  cardiac  examinations.
Management of symptomatic patients
Treatment  is  tailored  to  each  situation.  No  treatment  is
recommended  in  asymptomatic  subjects.  In  symptomatic
patients,  regardless  of  the  presence  or  absence  of  gradi-
ent,  the  recommended  initial  treatment  is  still  high-dose
beta-blockers.  In  case  of  intolerance  of  contraindication  to
beta-blockers,  verapamil  can  be  used.  Disopyramide  may
be  combined  with  beta-blockers  to  reduce  the  gradient
in  symptomatic  patients,  with  monitoring  of  possible  side
effects.  In  symptomatic  children,  beta-blockers  are  also  the
treatment  of  choice.  Diuretics  should  be  used  exceedingly
carefully.  In  patients  resistant  to  medical  treatment,  the
management  will  be  different  according  to  the  presence  or
absence  of  LVOT  obstruction.  In  case  of  obstruction,  guide-
lines  recommend  a  rigorous  evaluation  by  an  experienced
multidisciplinary  team.  Strategies  of  ‘septal  reduction’  are
indicated  in  patients  in  New  York  Heart  Association  (NYHA)
functional  class  III—IV  despite  maximum-tolerated  medical
therapy,  with  a  gradient  >  50  mmHg;  they  may  also  be  rec-
ommended  for  patients  with  a  gradient  and  unexplained
recurrent  syncope.  Myomectomy  surgery  (ventricular  sep-
tal  myectomy  [Morrow  procedure])  is  the  recommended
treatment  in  young  subjects  and  in  patients  with  other
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esions  requiring  surgical  intervention  (coronary  revascu-
arization  or  concomitant  mitral  valve  surgery  [for  organic
itral  regurgitation]).  Septal  alcohol  ablation  is  an  alterna-
ive  to  surgery  in  other  situations  and  should  be  performed  in
xperienced  centres.  Myomectomy  and  septal  alcohol  abla-
ion  can  be  discussed  in  case  of  septal  hypertrophy  ≥  17  mm.
n  symptomatic  patients  with  obstruction,  but  with  a  con-
raindication  to  septal  reduction  (myomectomy  or  alcohol
blation)  or  with  a  high  risk  of  developing  heart  block  follow-
ng  septal  alcohol  ablation  or  septal  myectomy,  sequential
trioventricular  pacing  is  possible  to  reduce  the  gradient
nd  facilitate  the  strengthening  of  medical  treatment  [6].
n  case  of  indication  for  ICD,  a  dual-chamber  ICD  may  be  con-
idered  in  patients  with  LVOT  obstruction  ≥  50  mmHg,  sinus
hythm  and  drug-refractory  symptoms.  Finally,  LV  mid-cavity
bstruction  remains  rare.  Negative  inotropic  treatment
beta-blockers,  verapamil  or  diltiazem)  is  still  required  but
he  response  is  often  suboptimal.  Left  ventricular  apical
neurysms  may  develop  ventricular  tachycardia  related  to
djacent  apical  scarring  or  thrombus,  needing  speciﬁc  treat-
ent.  However,  the  risk  of  sudden  death  is  unclear,  but
rophylactic  ICD  implantation  is  not  recommended  in  the
bsence  of  other  sudden-death  risk  factors.
In  case  of  heart  failure,  if  the  LV  ejection  fraction
s  ≥  50%,  beta-blockers  remain  the  treatment  of  choice.
ow-dose  loop  or  thiazide  diuretics  may  be  used  cautiously,
ut  it  is  important  to  avoid  hypovolaemia.  In  patients  in
YHA  functional  class  II—IV  and  with  atrial  ﬁbrillation,
ardioversion  is  necessary.  Angiotensin-converting  enzyme
nhibitors  may  be  combined  with  beta-blockers,  especially
n  patients  with  LV  ejection  fraction  <  50%  and  particularly  in
hose  with  no  LVOT  obstruction.  Finally,  cardiac  transplan-
ation  is  possible  in  case  of  depressed  LV  ejection  fraction
ith  NYHA  functional  class  III—IV  despite  adequate  treat-
ent.  Chest  pain  during  exercise  without  LVOT  obstruction
lso  needs  beta-blockers  or  calcium  antagonists.  Nitrates
hould  only  be  reserved  for  patients  with  angina  without
VOT  obstruction.
Anticoagulant  therapy  is  recommended  for  atrial  arrhyth-
ias  (ﬁbrillation  or  ﬂutter),  even  when  sinus  rhythm  is
estored.  The  evaluation  of  the  risk  of  bleeding  should  be
one  with  the  HAS-BLED  score.  The  use  of  the  CHA2DS2-VASc
core  is  not  recommended,  but  in  case  of  HCM,  it  is  of  impor-
ance  to  assess  the  size  of  the  left  atrium.  The  recommended
nticoagulant  is  a  vitamin  K  antagonist,  but  in  case  of  failure
o  maintain  therapeutic  anticoagulation  or  vitamin  K  antag-
nist  side  effects,  a  direct  thrombin  inhibitor  (dabigatran)
r  oral  factor  Xa  inhibitor  (rivaroxaban,  apixaban)  may  be
roposed.  Dual  antiplatelet  therapy  may  be  discussed  as  a
ubstitute  for  patients  with  a  contraindication  to  anticoagu-
ant.  Restoration  of  sinus  rhythm  is  recommended  by  direct
urrent  or  pharmacological  cardioversion.  Amiodarone  is  the
reatment  of  choice  for  maintenance  of  sinus  rhythm.  Beta-
lockers  can  be  used  to  maintain  a  resting  heart  rate  <  100
eats  per  minute  in  patients  with  permanent  atrial  ﬁbrilla-
ion.  Finally,  the  reduction  of  atrial  ﬁbrillation  by  catheter
blation  should  be  considered  in  patients  without  severe  left
trial  enlargement,  who  have  drug  refractory  symptoms  or
re  unable  to  take  antiarrhythmic  drugs.  Ablation  of  the
trioventricular  node  may  be  considered  to  control  heart
ate,  with  the  implantation  of  a  dual-chamber  pacemaker
if  LV  ejection  fraction  ≥  50%),  a  single-chamber  pacemaker
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if  there  is  atrial  ﬁbrillation)  or  cardiac  resynchronisation
herapy  pacemaker  (if  LV  ejection  fraction  <  50%).
anagement of the risk of sudden death
he  main  innovation  of  these  recommendations  is  the  eval-
ation  of  sudden  death  in  primary  prevention,  based  on
 study  published  recently  in  the  European  Heart  Journal
7].  There  are  seven  markers  estimating  sudden  cardiac
eath  risk:  age;  family  history  of  sudden  cardiac  death  at  a
oung  age;  maximum  LV  wall  thickness;  left  atrial  diameter;
VOT  obstruction;  non-sustained  ventricular  tachycardia;
nd  unexplained  syncope.
A  complex  formula  has  been  developed  to  calculate  the
ndividualized  5-year  risk,  and  is  available  online  [8]. This
ormula  has  been  validated  in  an  impressive  replication  pop-
lation  (total  n  =  3675  patients),  although  it  presents  several
imitations.  It  is  not  applicable  in  several  cases:  before  age
6  years;  in  elite/competitive  athletes;  in  patients  with
etabolic  disease;  and  in  case  of  malformation  syndromes.
his  proposed  model  no  longer  uses  assessment  of  blood
ressure  during  exercise,  has  not  been  validated  after  sep-
al  alcohol  ablation  or  myomectomy  and  can  only  be  used
or  a  maximum  LV  wall  thickness  <  35  mm.  According  to  this
core,  in  primary  prevention,  patients  are  classiﬁed  into
hree  categories:  low  risk  (<  4%);  intermediate  risk  (4—6%);
nd  high  risk  (>  6%).  In  patients  with  a  risk  <  4%,  there  is  usu-
lly  no  indication  for  prophylactic  ICD  implantation,  whereas
n  patients  with  a  risk  >  6%,  ICD  implantation  should  be
onsidered.  In  patients  with  a  risk  of  4—6%,  a  deﬁbrilla-
or  can  be  considered.  The  assessment  of  this  risk  score
ust  be  repeated  every  1—2  years  or  in  case  of  clinical
hanges.  In  secondary  prevention,  after  cardiac  arrest  due
o  ventricular  tachycardia  or  ﬁbrillation  or  in  case  of  spon-
aneous  sustained  ventricular  tachycardia  causing  syncope
r  haemodynamic  compromise,  ICD  implantation  is  recom-
ended.  The  restriction  of  competitive  sports  is  also  the
ule  in  any  patient  with  HCM,  regardless  of  arrhythmic  risk.
outine follow-up
uidelines  recommend  regular  follow-up  with  clinical  exam-
nation,  12-lead  ECG  and  transthoracic  echocardiography
very  12—24  months  in  clinically  stable  patients.  A  closer
valuation  is  necessary  in  case  of  symptoms.  A  48-hour
mbulatory  ECG  is  recommended  every  12—24  months  in  sta-
le  patients,  every  6—12  months  in  patients  in  sinus  rhythm
ith  left  atrial  dimension  ≥  45  mm  and  whenever  patients
omplain  of  new  palpitations.  CMR  may  be  considered  sys-
ematically  every  5  years  in  clinically  stable  patients  and
very  2—3  years  in  patients  with  progressive  disease.  Finally,
xercise  testing  may  be  considered  every  2—3  years  in  stable
atients  and  every  year  in  case  of  progressive  symptoms.
eproduction and contraceptionregnancy  is  associated  with  physiological  changes:  40—50%
ncrease  in  plasma  volume  and  cardiac  output;  reduction
n  systemic  vascular  resistance;  and  hypercoagulable  state.
R
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aternal  risk  is  low  in  women  with  HCM  when  symptoms  are
odest  or  absent  and  when  the  gradient  is  absent  or  non-
igniﬁcant.  However,  an  increased  risk  for  mother  and  foetus
s  observed  in  patients  with  signiﬁcant  LVOT  obstruction,
igniﬁcant  symptoms  and/or  LV  dysfunction.  Prepregnancy
isk  assessment  and  counselling  is  indicated  in  all  women.
ounselling  on  the  risk  of  disease  transmission  and  contra-
eption  is  recommended  before  conception.  Beta-blockers
especially  metoprolol)  should  be  continued  during  preg-
ancy,  if  they  were  used  before,  or  should  be  started  at  the
nset  of  symptoms  during  pregnancy.  Monitoring  of  foetal
rowth  during  pregnancy  and  the  condition  of  the  neonate
s  necessary.  Scheduled  vaginal  delivery  is  possible  and  rec-
mmended.  Pregnant  women  with  atrial  ﬁbrillation  need
herapeutic  anticoagulation  (low-molecular-weight  heparin
r  vitamin  K  antagonists  depending  on  the  stage  of  preg-
ancy)  and  cardioversion  may  be  performed  to  restore  sinus
hythm  as  much  as  possible.
ifestyle considerations
ompetitive  sports  activities  are  contraindicated  and  recre-
tional  activities  should  be  tailored  to  symptoms  and  the  risk
f  disease-related  complications.  Weight  should  be  moni-
ored  and  dehydration  and  excess  alcohol  should  be  avoided.
exual  activity  may  be  normal,  but  the  use  of  phosphodieste-
ase  type  5  inhibitors  should  be  avoided,  particularly  in  case
f  LVOT  obstruction.  Physicians  must  inform  their  patients
bout  their  medication,  including  potential  side  effects  and
nteractions  with  prescribed  medications,  and  they  must
ecommend  vaccinations.  Most  patients  with  HCM  are  eli-
ible  for  an  ordinary  driving  licence  and,  in  case  of  ICD,  it  is
ecommended  to  follow  the  European  Heart  Rhythm  Associa-
ion  (EHRA)  guidance  and  local  recommendations  from  each
ountry.  Patients  with  HCM  will  be  able  to  continue  their
obs,  except  for  heavy  manual  jobs  with  strenuous  activ-
ty,  the  implications  of  which  should  be  discussed  with  the
ppropriate  specialist.  Finally,  advice  is  given  about  insur-
nce  companies,  life  insurance  and  knowledge  of  the  disease
n  teachers  of  children  with  HCM.
ummary
hese  precise  recommendations  allow  global  management
f  hypertrophic  cardiomyopathy,  with  detailed  tables  and
ists  of  drugs  that  can  be  used  or  are  contraindicated.  The
ain  innovation  is  the  evaluation  of  the  5-year  risk  of  sudden
eath  in  primary  prevention  using  a  new  calculator  [8].
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